Immunotherapy has shown promise in select patients with gastrointestinal (GI) malignancies, but challenges remain in immune recognition and optimal sequencing, says Gregory L. Beatty, MD, PhD.
Cancers that form in the GI tract often avoid immune recognition, but patients who have mismatch repair-deficient (dMMR) cancers have larger mutational loads, making it easier for the immune system to recognize those tumors. Read more . . .